Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00086658
First received: July 7, 2004
Last updated: November 1, 2012
Last verified: October 2012